Skip to main content
. 2021 Aug 2;8(9):1817–1830. doi: 10.1002/acn3.51435

Figure 1.

Figure 1

MAPT R406W carriers have increased CSF pT217/T217 without Amyloid pathology. (A) All samples (n = 252) were plotted to quadrant analyses using the cutoffs calculated in the WashU‐A cohort (CSF Aβ 42/40 cutoff = 0.086, CSF pT217/T217 cutoff = 4.76). (B–E) Pie charts showing the number of participants in each clinically classified group for each quadrant: II (B), I (C), III (D), and IV (E). CSF, cerebrospinal fluid.